CLINUVEL PHARMACEUTICALS

Company snapshot

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CLINUVEL PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CLINUVEL PHARMACEUTICALS.

1. Jun 5, 2026 Clinical update

   PRENUMBRA — Phase 2

2. Jun 5, 2026 Clinical update

   PRENUMBRA — Phase 2

3. May 26, 2026 Clinical update

   PRENUMBRA — Phase 2

4. May 26, 2026 Clinical update

   SCENESSE 16 mg implant — Phase 2

5. May 26, 2026 Clinical update

   SCENESSE 16 mg implant — Phase 3

View all clinical trial activity →

• What is CLINUVEL PHARMACEUTICALS?

  Clinuvel Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Vitiligo, Erythropoietic Protoporphyria (EPP), Parkinson's Disease, Arterial Ischaemic Stroke (AIS). NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 0 patent r

• Is CLINUVEL PHARMACEUTICALS publicly traded?

  CLINUVEL PHARMACEUTICALS appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CLINUVEL PHARMACEUTICALS develop or market?

  We link 3 drug profile(s) where CLINUVEL PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/clinuvel-europe-limited#company-drugs.

• What are the latest developments for CLINUVEL PHARMACEUTICALS?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CLINUVEL PHARMACEUTICALS focus on?

  CLINUVEL PHARMACEUTICALS focuses on Vitiligo, Erythropoietic Protoporphyria (EPP), Parkinson's Disease based on our analysis of their pipeline programs and drug development activities.